KDR and renal cell adenocarcinoma: Checkmate 025 was the first large phase III clinical trials comparing the PD-1 inhibitor nivolumab to everolimus in patients with locally advanced or metastatic RCC progressed to at least one VEGF/VEGFR inhibitor (11).